BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guney Eskiler G, Cecener G, Dikmen G, Egeli U, Tunca B. Solid lipid nanoparticles: Reversal of tamoxifen resistance in breast cancer. Eur J Pharm Sci 2018;120:73-88. [PMID: 29719240 DOI: 10.1016/j.ejps.2018.04.040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 El-menshawe SF, Sayed OM, Abou Taleb HA, Saweris MA, Zaher DM, Omar HA. The use of new quinazolinone derivative and doxorubicin loaded solid lipid nanoparticles in reversing drug resistance in experimental cancer cell lines: A systematic study. Journal of Drug Delivery Science and Technology 2020;56:101569. [DOI: 10.1016/j.jddst.2020.101569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
2 Day CM, Hickey SM, Song Y, Plush SE, Garg S. Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles. Molecules. 2020;25. [PMID: 32151063 DOI: 10.3390/molecules25051182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
3 Allahverdiyev AM, Parlar E, Dinparvar S, Bagirova M, Abamor EŞ. Current aspects in treatment of breast cancer based of nanodrug delivery systems and future prospects. Artif Cells Nanomed Biotechnol 2018;46:S755-62. [PMID: 30260234 DOI: 10.1080/21691401.2018.1511573] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
4 Fonseca-Gomes J, Loureiro JA, Tanqueiro SR, Mouro FM, Ruivo P, Carvalho T, Sebastião AM, Diógenes MJ, Pereira MC. In vivo Bio-Distribution and Toxicity Evaluation of Polymeric and Lipid-Based Nanoparticles: A Potential Approach for Chronic Diseases Treatment. Int J Nanomedicine 2020;15:8609-21. [PMID: 33177821 DOI: 10.2147/IJN.S267007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
5 Sengupta P, Choudhury H, Dutta S, Jacob S, Kesharwani P, Gorain B. Current Strategies in Breast Cancer Therapy: Role of Epigenetics and Nanomedicine. Part & Part Syst Charact. [DOI: 10.1002/ppsc.202100276] [Reference Citation Analysis]
6 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer. Pharm Res 2018;35. [DOI: 10.1007/s11095-018-2502-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
7 Yao J, Deng K, Huang J, Zeng R, Zuo J. Progress in the Understanding of the Mechanism of Tamoxifen Resistance in Breast Cancer. Front Pharmacol 2020;11:592912. [PMID: 33362547 DOI: 10.3389/fphar.2020.592912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hallan SS, Amirian J, Brangule A, Bandere D. Lipid-Based Nano-Sized Cargos as a Promising Strategy in Bone Complications: A Review. Nanomaterials (Basel) 2022;12:1146. [PMID: 35407263 DOI: 10.3390/nano12071146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Rajpoot K. Solid Lipid Nanoparticles: A Promising Nanomaterial in Drug Delivery. Curr Pharm Des 2019;25:3943-59. [PMID: 31481000 DOI: 10.2174/1381612825666190903155321] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
10 Barazetti JF, Jucoski TS, Carvalho TM, Veiga RN, Kohler AF, Baig J, Al Bizri H, Gradia DF, Mader S, Carvalho de Oliveira J. From Micro to Long: Non-Coding RNAs in Tamoxifen Resistance of Breast Cancer Cells. Cancers (Basel) 2021;13:3688. [PMID: 34359587 DOI: 10.3390/cancers13153688] [Reference Citation Analysis]
11 Ashtari A, Niazvand F, Khorsandi L. Chemotherapy Drugs Based on Solid Lipid Nanoparticles for Breast Cancer Treatment. Medicina (Kaunas) 2020;56:E694. [PMID: 33322127 DOI: 10.3390/medicina56120694] [Reference Citation Analysis]
12 Cerqueira M, Belmonte-reche E, Gallo J, Baltazar F, Bañobre-lópez M. Magnetic Solid Nanoparticles and Their Counterparts: Recent Advances towards Cancer Theranostics. Pharmaceutics 2022;14:506. [DOI: 10.3390/pharmaceutics14030506] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Talazoparib nanoparticles for overcoming multidrug resistance in triple-negative breast cancer. J Cell Physiol 2020;235:6230-45. [PMID: 32017076 DOI: 10.1002/jcp.29552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Rajpoot K. Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications. Curr Cancer Drug Targets 2020;20:271-87. [PMID: 31951180 DOI: 10.2174/1568009620666200115160805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Sartaj A, Baboota S, Ali J. Nanomedicine: A Promising Avenue for the Development of Effective Therapy for Breast Cancer. Curr Cancer Drug Targets 2020;20:603-15. [PMID: 32228423 DOI: 10.2174/1568009620666200331124113] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Tran P, Lee S, Kim D, Pyo Y, Park J. Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment. J Pharm Investig 2020;50:261-70. [DOI: 10.1007/s40005-019-00459-7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 9.3] [Reference Citation Analysis]
17 Lerata MS, D'Souza S, Sibuyi NRS, Dube A, Meyer M, Samaai T, Antunes EM, Beukes DR. Encapsulation of Variabilin in Stearic Acid Solid Lipid Nanoparticles Enhances Its Anticancer Activity in Vitro. Molecules 2020;25:E830. [PMID: 32074951 DOI: 10.3390/molecules25040830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
18 Bayón-Cordero L, Alkorta I, Arana L. Application of Solid Lipid Nanoparticles to Improve the Efficiency of Anticancer Drugs. Nanomaterials (Basel) 2019;9:E474. [PMID: 30909401 DOI: 10.3390/nano9030474] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 18.3] [Reference Citation Analysis]
19 Al-Jubori AA, Sulaiman GM, Tawfeeq AT, Mohammed HA, Khan RA, Mohammed SAA. Layer-by-Layer Nanoparticles of Tamoxifen and Resveratrol for Dual Drug Delivery System and Potential Triple-Negative Breast Cancer Treatment. Pharmaceutics 2021;13:1098. [PMID: 34371789 DOI: 10.3390/pharmaceutics13071098] [Reference Citation Analysis]
20 Afzal M, Ameeduzzafar, Alharbi KS, Alruwaili NK, Al-Abassi FA, Al-Malki AAL, Kazmi I, Kumar V, Kamal MA, Nadeem MS, Aslam M, Anwar F. Nanomedicine in treatment of breast cancer - A challenge to conventional therapy. Semin Cancer Biol 2021;69:279-92. [PMID: 31870940 DOI: 10.1016/j.semcancer.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
21 Yap KM, Sekar M, Fuloria S, Wu YS, Gan SH, Mat Rani NNI, Subramaniyan V, Kokare C, Lum PT, Begum MY, Mani S, Meenakshi DU, Sathasivam KV, Fuloria NK. Drug Delivery of Natural Products Through Nanocarriers for Effective Breast Cancer Therapy: A Comprehensive Review of Literature. Int J Nanomedicine 2021;16:7891-941. [PMID: 34880614 DOI: 10.2147/IJN.S328135] [Reference Citation Analysis]